1921
Volume 93, Issue 2
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

In tuberculosis (TB)–prevalent settings, patients admitted for retreatment of TB may account for a high burden of poor treatment outcome. We performed a retrospective cohort study to characterize retreatment patients and outcomes at a TB referral hospital in northern Tanzania. From 2009 to 2013, 185 patients began a retreatment regimen, the majority for relapse after prior treatment completion. Men accounted for an unexpected majority (88%), 36 (20%) were human immunodeficiency virus (HIV) infected and for 45 (24%) mining was their primary occupation. A poor outcome (death, default, or persistent smear positivity after 7 months of treatment) was found in 37 (23%). HIV infection was the only significant predictor of poor outcome (adjusted odds ratio [aOR] = 2.50, 95% confidence interval [CI] = 1.07–5.83, = 0.034). Interventions to minimize need for retreatment or improve retreatment success may be regionally specific. In our setting, community-based diagnosis and management among at-risk subpopulations such as miners and those HIV infected appear of highest yield.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.15-0189
2015-08-05
2020-08-03
Loading full text...

Full text loading...

/deliver/fulltext/14761645/93/2/212.html?itemId=/content/journals/10.4269/ajtmh.15-0189&mimeType=html&fmt=ahah

References

  1. World Health Organization, 2015. World Health Organization Country Fact Sheet, Tuberculosis, Tanzania, 2015. Geneva, Switzerland: World Health Organization. Available at: http://www.who.int/tb/country/data/profiles/en/. Accessed March 31, 2015.
    [Google Scholar]
  2. Peloquin CA, Berning SE, Nitta AT, Simone PM, Goble M, Huitt GA, Iseman MD, Cook JL, Curran-Everett D, 2004. Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases. Clin Infect Dis 38: 15381544.[Crossref]
    [Google Scholar]
  3. Bratviet M, Moen BE, Mashalla YJS, Maalim H, 2003. Dust exposure during small-scale mining in Tanzania: a pilot study. Ann Occup Hyg 47: 235240.
    [Google Scholar]
  4. Rees D, Murrary J, 2007. Silica, silicosis and tuberculosis. Int J Tuberc Lung Dis 11: 474484.
    [Google Scholar]
  5. United Republic of Tanzania: Ministry of Health and Social Welfare (MoH and SW), 2006. National TB and Leprosy Program, Clinical Guideline for TB Management. Dar es Salaam, United Republic of Tanzania: MoH and SW.
    [Google Scholar]
  6. Mpagama S, Heysell SK, Ndusilo ND, Kumburu HH, Lekule IA, Kisonga RM, Gratz J, Boeree MJ, Houpt ER, Kibiki GS, 2013. Diagnosis and interim treatment outcomes from the first cohort of multidrug-resistant tuberculosis patients in Tanzania. PLoS One 8: e62034.[Crossref]
    [Google Scholar]
  7. Burton NT, Forson A, Lurie MN, Kudzawa S, Kwarteng E, Kwara A, 2011. Factors associated with mortality and default among patients with tuberculosis attending a teaching hospital clinic in Accra, Ghana. Trans R Soc Trop Med Hyg 105: 675682.[Crossref]
    [Google Scholar]
  8. Heysell SK, Mtabho C, Mpagama S, Mwaigwisya S, Ndusilo N, Pholwat S, Gratz J, Aarnouste R, Kibiki GS, Houpt ER, 2011. A plasma drug activity assay for treatment optimization in tuberculosis patients. Antimicrob Agents Chemother 55: 58195825.[Crossref]
    [Google Scholar]
  9. Tostmann A, Mtabho CM, Semvua HH, van den Boogaard J, Kibiki GS, Boeree MJ, Aarnoutse RE, 2013. Pharmacokinetics of first-line tuberculosis drugs in Tanzanian patients. Antimicrob Agents Chemother 57: 32083213.[Crossref]
    [Google Scholar]
  10. Hoa NB, Lauritsen JM, Rieder HL, 2013. Changes in body weight and tuberculosis treatment outcome in Viet Nam. Int J Tuberc Lung Dis 17: 6166.[Crossref]
    [Google Scholar]
  11. Barroso EC, Pinheiro VGF, Facanha MC, Carvalho MRD, Moura ME, Campelo CL, Peloquin CA, Guerrant RL, Lima AAM, 2009. Serum concentrations of rifampin, isoniazid and intestinal absorption, permeability in patients with multidrug resistant tuberculosis. Am J Trop Med Hyg 81: 322329.
    [Google Scholar]
  12. van Ingen J, Aarnoutse RE, Donald PR, Diacon AH, Dawson R, van Balen GP, Gillespie SH, Boeree MJ, 2011. Why do we use 600 mg of rifampicin in tuberculosis treatment? Clin Infect Dis 52: e194e199.[Crossref]
    [Google Scholar]
  13. Reynolds J, Heysell SK, 2014. Understanding pharmacokinetics to improve tuberculosis treatment outcome. Expert Opin Drug Metab Toxicol 10: 813823.[Crossref]
    [Google Scholar]
  14. Jacob ST, Banura P, Baeten JM, Moore CC, Meya D, Nakiyingi L, Burke R, Horton CL, Iga B, Wald A, Reynolds SJ, Mayanja-Kizza H, Scheld WM, 2012. The impact of early monitored management on survival in hospitalized adult Ugandan patients with severe sepsis: a prospective intervention study. Crit Care Med 40: 20502058.[Crossref]
    [Google Scholar]
  15. Heysell SK, Thomas TA, Moll AP, Gandhi NR, Eksteen FJ, Babaria P, Roux L, Coovadia Y, Lallo U, Friedland G, Shah NS, 2010. Blood cultures for the diagnosis of multidrug-resistant and extensively drug-resistant tuberculosis among HIV-infected patients from rural South Africa. BMC Infect Dis 10: 344.[Crossref]
    [Google Scholar]
  16. TB CARE I, 2014. International Standards for Tuberculosis Care, 3rd edition. The Hague, The Netherlands: TB CARE I.
    [Google Scholar]
  17. Srivastava S, Pasipanodya JG, Meek C, Leff R, Gumbo T, 2011. Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability. J Infect Dis 204: 19511959.[Crossref]
    [Google Scholar]
  18. Stuckler D, Basu S, McKee M, Lurie M, 2011. Mining and risk of tuberculosis in sub-Saharan Africa. Am J Public Health 101: 524530.[Crossref]
    [Google Scholar]
  19. Hnizdo E, Murray J, 1998. Risk of pulmonary tuberculosis relative to silicosis and exposure to silica dust in South African gold miners. Occup Environ Med 55: 496502.[Crossref]
    [Google Scholar]
  20. Churchyard G, Kleinschmidt I, Corbett EL, Murray J, Smit J, De Cock KM, 2000. Factors associated with an increased case-fatality rate in HIV-infected and non-infected South African gold miners with pulmonary tuberculosis. Int J Tuberc Lung Dis 4: 705712.
    [Google Scholar]
  21. Basu S, Stuckler D, McKee M, 2011. Addressing institutional amplifiers in the dynamics and control of tuberculosis epidemics. Am J Trop Med Hyg 84: 3037.[Crossref]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.15-0189
Loading
/content/journals/10.4269/ajtmh.15-0189
Loading

Data & Media loading...

  • Received : 10 Mar 2015
  • Accepted : 03 Apr 2015
  • Published online : 05 Aug 2015
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error